Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Josef M. Penninger is active.

Publication


Featured researches published by Josef M. Penninger.


Cardiovascular Research | 2017

ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage

Teruki Sato; Chitose Sato; Ayumi Kadowaki; Hiroyuki Watanabe; Lena Ho; Junji Ishida; Tomokazu Yamaguchi; Akinori Kimura; Akiyoshi Fukamizu; Josef M. Penninger; Bruno Reversade; Hiroshi Ito; Yumiko Imai; Keiji Kuba

AimsnElabela/Toddler/Apela (ELA) has been identified as a novel endogenous peptide ligand for APJ/Apelin receptor/Aplnr. ELA plays a crucial role in early cardiac development of zebrafish as well as in maintenance of self-renewal of human embryonic stem cells. Apelin was the first identified APJ ligand, and exerts positive inotropic heart effects and regulates the renin-angiotensin system. The aim of this study was to investigate the biological effects of ELA in the cardiovascular system.nnnMethods and resultsnContinuous infusion of ELA peptide significantly suppressed pressure overload-induced cardiac hypertrophy, fibrosis and impaired contractility in mice. ELA treatment reduced mRNA expression levels of genes associated with heart failure and fibrosis. The cardioprotective effects of ELA were diminished in APJ knockout mice, indicating that APJ is the key receptor for ELA in the adult heart. Mechanistically, ELA downregulated angiotensin-converting enzyme (ACE) expression in the stressed hearts, whereas it showed little effects on angiotensin-converting enzyme 2 (ACE2) expression, which are distinct from the effects of Apelin. FoxM1 transcription factor, which induces ACE expression in the stressed hearts, was downregulated by ELA but not by Apelin. ELA antagonized angiotensin II-induced hypertension, cardiac hypertrophy, and fibrosis in mice.nnnConclusionnThe ELA-APJ axis protects from pressure overload-induced heart failure possibly via suppression of ACE expression and pathogenic angiotensin II signalling. The different effects of ELA and Apelin on the expression of ACE and ACE2 implicate fine-tuned mechanisms for a ligand-induced APJ activation and downstream signalling.


Oncotarget | 2017

Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer

Stefan Kiechl; Daniel Schramek; Martin Widschwendter; Evangelia-Ourania Fourkala; Alexey Zaikin; Allison Jones; Bernadette Jaeger; Brigitte Rack; Wolfgang Janni; Christoph Scholz; Johann Willeit; Siegfried Weger; Agnes Mayr; Andrew E. Teschendorff; Adam N. Rosenthal; Lindsay Fraser; Susan Philpott; Louis Dubeau; Mohammed Keshtgar; Rebecca Roylance; Ian Jacobs; Usha Menon; Georg Schett; Josef M. Penninger

Breast cancer is the most common female cancer, affecting approximately one in eight women during their lifetime in North America and Europe. Receptor Activator of NF-kB Ligand (RANKL), its receptor RANK and the natural antagonist osteoprotegerin (OPG) are essential regulators of bone resorption. We have initially shown that RANKL/RANK are essential for hormone-driven mammary epithelial proliferation in pregnancy and RANKL/RANK have been implicated in mammary stem cell biology. Using genetic mouse-models, we and others identified the RANKL/RANK system as a key regulator of sex hormone, BRCA1-mutation, and oncogene-driven breast cancer and we proposed that RANKL/RANK might be involved in the initiation of breast tumors. We now report that in postmenopausal women without known genetic predisposition, high RANKL and progesterone serum levels stratify a subpopulation of women at high risk of developing breast cancer 12-24 months before diagnosis (5.33-fold risk, 95%CI 1.5-25.4; P=0.02). In women with established breast cancer, we demonstrate that RANKL/OPG ratios change dependent on the presence of circulating tumor cells (CTCs). Finally, we show in a prospective human breast cancer cohort that alterations in RANKL/OPG ratios are significantly associated with breast cancer manifestation. These data indicate that the RANKL/RANK/OPG system is deregulated in post-menopausal women at high risk for breast cancer and in women with circulating tumor cells. Thus, serum levels of RANKL/OPG are potentially indicative of predisposition and progression of breast cancer in humans. Advancement of our findings towards clinical application awaits prior validation in independent patient cohorts.


Nature | 2018

Coupling of bone resorption and formation by RANKL reverse signalling

Yuki Ikebuchi; Shigeki Aoki; Masashi Honma; Madoka Hayashi; Yasutaka Sugamori; Masud Khan; Yoshiaki Kariya; Genki Kato; Yasuhiko Tabata; Josef M. Penninger; Nobuyuki Udagawa; Kazuhiro Aoki; Hiroshi Suzuki

Receptor activator of nuclear factor-kappa B (RANK) ligand (RANKL) binds RANK on the surface of osteoclast precursors to trigger osteoclastogenesis. Recent studies have indicated that osteocytic RANKL has an important role in osteoclastogenesis during bone remodelling; however, the role of osteoblastic RANKL remains unclear. Here we show that vesicular RANK, which is secreted from the maturing osteoclasts, binds osteoblastic RANKL and promotes bone formation by triggering RANKL reverse signalling, which activates Runt-related transcription factor 2 (Runx2). The proline-rich motif in the RANKL cytoplasmic tail is required for reverse signalling, and axa0RANKL(Pro29Ala) point mutation reduces activation of the reverse signalling pathway. The coupling of bone resorption and formation is disrupted in RANKL(Pro29Ala) mutant mice, indicating that osteoblastic RANKL functions as a coupling signal acceptor that recognizes vesicular RANK. RANKL reverse signalling is therefore a potential pharmacological target for avoiding the reduced bone formation associated with inhibition of osteoclastogenesis.Osteoclasts secrete small extracellular vesicles that stimulate osteoblasts, promoting bone formation via receptor activator of nuclear factor-kappa B ligand (RANKL), thereby linking bone formation and resorption.


Psychopharmacology | 2017

Mice haploinsufficient for Map2k7, a gene involved in neurodevelopment and risk for schizophrenia, show impaired attention, a vigilance decrement deficit and unstable cognitive processing in an attentional task: impact of minocycline

R.L. Openshaw; David M. Thomson; Josef M. Penninger; Judith A. Pratt; Brian J. Morris

RationaleMembers of the c-Jun N-terminal kinase (JNK) family of mitogen-activated protein (MAP) kinases, and the upstream kinase MKK7, have all been strongly linked with synaptic plasticity and with the development of the neocortex. However, the impact of disruption of this pathway on cognitive function is unclear.ObjectiveIn the current study, we test the hypothesis that reduced MKK7 expression is sufficient to cause cognitive impairment.MethodsAttentional function in mice haploinsufficient for Map2k7 (Map2k7+/− mice) was investigated using the five-choice serial reaction time task (5-CSRTT).ResultsOnce stable performance had been achieved, Map2k7+/− mice showed a distinctive attentional deficit, in the form of an increased number of missed responses, accompanied by a more pronounced decrement in performance over time and elevated intra-individual reaction time variability. When performance was reassessed after administration of minocycline—a tetracycline antibiotic currently showing promise for the improvement of attentional deficits in patients with schizophrenia—signs of improvement in attentional performance were detected.ConclusionsOverall, Map2k7 haploinsufficiency causes a distinctive pattern of cognitive impairment strongly suggestive of an inability to sustain attention, in accordance with those seen in psychiatric patients carrying out similar tasks. This may be important for understanding the mechanisms of cognitive dysfunction in clinical populations and highlights the possibility of treating some of these deficits with minocycline.


Proceedings of the National Academy of Sciences of the United States of America | 2017

Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice

Miguel Á. Tejada; Ángeles Montilla-García; Shane J. Cronin; Domagoj Cikes; Cristina Sánchez-Fernández; Rafael González-Cano; M. Carmen Ruiz-Cantero; Josef M. Penninger; José Miguel Vela; José M. Baeyens; Enrique J. Cobos

Significance New pain medications with novel mechanisms of action are needed. Here we show that sigma-1 antagonism decreases inflammatory pain hypersensitivity by enhancing the actions of endogenous opioid peptides produced by leukocytes in mice. Sigma-1 antagonism results in opioid analgesia only at the inflamed site, where immune cells naturally accumulate. This mechanism, which maximizes the analgesic potential of immune cells in painful inflamed sites, differs from that of conventional analgesics. Sigma-1 antagonism potentiates the antinociceptive effects of opioid drugs, so sigma-1 receptors constitute a biological brake to opioid drug-induced analgesia. The pathophysiological role of this process is unknown. We aimed to investigate whether sigma-1 antagonism reduces inflammatory pain through the disinhibition of the endogenous opioidergic system in mice. The selective sigma-1 antagonists BD-1063 and S1RA abolished mechanical and thermal hyperalgesia in mice with carrageenan-induced acute (3 h) inflammation. Sigma-1–mediated antihyperalgesia was reversed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restricted naloxone analog) and by local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioid sequence Tyr–Gly–Gly–Phe at the N terminus of most endogenous opioid peptides (EOPs). Neutrophils expressed pro-opiomelanocortin, the precursor of β-endorphin (a known EOP), and constituted the majority of the acute immune infiltrate. β-endorphin levels increased in the inflamed paw, and this increase and the antihyperalgesic effects of sigma-1 antagonism were abolished by reducing the neutrophil load with in vivo administration of an anti-Ly6G antibody. The opioid-dependent sigma-1 antihyperalgesic effects were preserved 5 d after carrageenan administration, where macrophages/monocytes were found to express pro-opiomelanocortin and to now constitute the majority of the immune infiltrate. These results suggest that immune cells harboring EOPs are needed for the antihyperalgesic effects of sigma-1 antagonism during inflammation. In conclusion, sigma-1 receptors curtail immune-driven peripheral opioid analgesia, and sigma-1 antagonism produces local opioid analgesia by enhancing the action of EOPs of immune origin, maximizing the analgesic potential of immune cells that naturally accumulate in painful inflamed areas.


NeuroImage | 2017

Predicting functional neuroanatomical maps from fusing brain networks with genetic information

Florian Ganglberger; Joanna Kaczanowska; Josef M. Penninger; Andreas Hess; Katja Bühler; Wulf Haubensak

ABSTRACT Functional neuroanatomical maps provide a mesoscale reference framework for studies from molecular to systems neuroscience and psychiatry. The underlying structure‐function relationships are typically derived from functional manipulations or imaging approaches. Although highly informative, these are experimentally costly. The increasing amount of publicly available brain and genetic data offers a rich source that could be mined to address this problem computationally. Here, we developed an algorithm that fuses gene expression and connectivity data with functional genetic meta data and exploits cumulative effects to derive neuroanatomical maps related to multi‐genic functions. We validated the approach by using public available mouse and human data. The generated neuroanatomical maps recapture known functional anatomical annotations from literature and functional MRI data. When applied to multi‐genic meta data from mouse quantitative trait loci (QTL) studies and human neuropsychiatric databases, this method predicted known functional maps underlying behavioral or psychiatric traits. Taken together, genetically weighted connectivity analysis (GWCA) allows for high throughput functional exploration of brain anatomy in silico. It maps functional genetic associations onto brain circuitry for refining functional neuroanatomy, or identifying trait‐associated brain circuitry, from genetic data. HIGHLIGHTSGenetically weighted connectivity analysis (GWCA) builds on synergies from fusing genetic, gene expression and connectivity dataGWCA allows for high throughput functional exploration of brain anatomy in silicoCan be used to refine functional neuroanatomy from genetic dataCan be used to predict brain networks associated with behavioral or psychiatric traitsNodes can serve as entry points for functional circuit dissection.


Genes & Development | 2017

RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer

Shuan Rao; Verena Sigl; Reiner Wimmer; Maria Novatchkova; Alexander Jais; Gabriel Wagner; Stephan Handschuh; Iris Uribesalgo; Astrid Hagelkruys; Ivona Kozieradzki; Luigi Tortola; Roberto Nitsch; Shane J. Cronin; Michael Orthofer; Daniel Branstetter; Jude Canon; John M. Rossi; Manolo D'Arcangelo; Johan Botling; Patrick Micke; Linnea La Fleur; Karolina Edlund; Michael Bergqvist; Simon Ekman; Thomas Lendl; Helmut Popper; Hiroshi Takayanagi; Lukas Kenner; Fred R. Hirsch; William C. Dougall

Lung cancer is the leading cause of cancer deaths. Besides smoking, epidemiological studies have linked female sex hormones to lung cancer in women; however, the underlying mechanisms remain unclear. Here we report that the receptor activator of nuclear factor-kB (RANK), the key regulator of osteoclastogenesis, is frequently expressed in primary lung tumors, an active RANK pathway correlates with decreased survival, and pharmacologic RANK inhibition reduces tumor growth in patient-derived lung cancer xenografts. Clonal genetic inactivation of KRasG12D in mouse lung epithelial cells markedly impairs the progression of KRasG12D -driven lung cancer, resulting in a significant survival advantage. Mechanistically, RANK rewires energy homeostasis in human and murine lung cancer cells and promotes expansion of lung cancer stem-like cells, which is blocked by inhibiting mitochondrial respiration. Our data also indicate survival differences in KRasG12D -driven lung cancer between male and female mice, and we show that female sex hormones can promote lung cancer progression via the RANK pathway. These data uncover a direct role for RANK in lung cancer and may explain why female sex hormones accelerate lung cancer development. Inhibition of RANK using the approved drug denosumab may be a therapeutic drug candidate for primary lung cancer.


Cell Research | 2017

A vital sugar code for ricin toxicity

Jasmin Taubenschmid; Johannes Stadlmann; Markus Jost; Tove Irene Klokk; Cory D. Rillahan; Karl Mechtler; James C. Paulson; Julian Jude; Johannes Zuber; Kirsten Sandvig; Ulrich Elling; Thorsten Marquardt; Christian Thiel; Christian Koerner; Josef M. Penninger

Ricin is one of the most feared bioweapons in the world due to its extreme toxicity and easy access. Since no antidote exists, it is of paramount importance to identify the pathways underlying ricin toxicity. Here, we demonstrate that the Golgi GDP-fucose transporter Slc35c1 and fucosyltransferase Fut9 are key regulators of ricin toxicity. Genetic and pharmacological inhibition of fucosylation renders diverse cell types resistant to ricin via deregulated intracellular trafficking. Importantly, cells from a patient with SLC35C1 deficiency are also resistant to ricin. Mechanistically, we confirm that reduced fucosylation leads to increased sialylation of Lewis X structures and thus masking of ricin-binding sites. Inactivation of the sialyltransferase responsible for modifications of Lewis X (St3Gal4) increases the sensitivity of cells to ricin, whereas its overexpression renders cells more resistant to the toxin. Thus, we have provided unprecedented insights into an evolutionary conserved modular sugar code that can be manipulated to control ricin toxicity.


Human Genetics | 2018

Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy

Joshi Stephen; Sheela Nampoothiri; Aditi Banerjee; Nathanial J. Tolman; Josef M. Penninger; Ullrich Elling; Chukwuma A. Agu; John Douglas Burke; Kalpana Devadathan; Rajesh Kannan; Yan Huang; Peter J. Steinbach; Susan A. Martinis; William A. Gahl; May Christine V. Malicdan

Progressive microcephaly and neurodegeneration are genetically heterogenous conditions, largely associated with genes that are essential for the survival of neurons. In this study, we interrogate the genetic etiology of two siblings from a non-consanguineous family with severe early onset of neurological manifestations. Whole exome sequencing identified novel compound heterozygous mutations in VARS that segregated with the proband: a missense (c.3192G>A; p.Met1064Ile) and a splice site mutation (c.1577-2A>G).xa0The VARS gene encodes cytoplasmic valyl-tRNA synthetase (ValRS), an enzyme that is essential during eukaryotic translation. cDNA analysis on patient derived fibroblasts revealed that the splice site acceptor variant allele led to nonsense mediated decay, thus resulting in axa0null allele. Three-dimensional modeling of ValRS predicts that the missense mutation lies in a highly conserved region and could alter side chain packing, thus affecting tRNA binding or destabilizing the interface between the catalytic and tRNA binding domains. Further quantitation of the expression of VARS showed remarkably reduced levels of mRNA and protein in skin derived fibroblasts. Aminoacylation experiments on patient derived cells showed markedly reduced enzyme activity of ValRS suggesting the mutations to be loss of function. Bi-allelic mutations in cytoplasmic amino acyl tRNA synthetases are well-known for their role in neurodegenerative disorders, yet human disorders associated with VARS mutations have not yet been clinically well characterized. Our study describes the phenotype associated with recessive VARS mutations and further functional delineation of the pathogenicity of novel variants identified, which widens the clinical and genetic spectrum of patients with progressive microcephaly.


Cellular and Molecular Life Sciences | 2018

Depletion of angiotensin-converting enzyme 2 reduces brain serotonin and impairs the running-induced neurogenic response

Friederike Klempin; Valentina Mosienko; Susann Matthes; Daniel C. Villela; Mihail Todiras; Josef M. Penninger; Michael Bader; Robson A.S. Santos; Natalia Alenina

Physical exercise induces cell proliferation in the adult hippocampus in rodents. Serotonin (5-HT) and angiotensin (Ang) II are important mediators of the pro-mitotic effect of physical activity. Here, we examine precursor cells in the adult brain of mice lacking angiotensin-converting enzyme (ACE) 2, and explore the effect of an acute running stimulus on neurogenesis. ACE2 metabolizes Ang II to Ang-(1–7) and is essential for the intestinal uptake of tryptophan (Trp), the 5-HT precursor. In ACE2-deficient mice, we observed a decrease in brain 5-HT levels and no increase in the number of BrdU-positive cells following exercise. Targeting the Ang II/AT1 axis by blocking the receptor, or experimentally increasing Trp/5-HT levels in the brain of ACE2-deficient mice, did not rescue the running-induced effect. Furthermore, mice lacking the Ang-(1–7) receptor, Mas, presented a normal neurogenic response to exercise. Our results identify ACE2 as a novel factor required for exercise-dependent modulation of adult neurogenesis and essential for 5-HT metabolism.

Collaboration


Dive into the Josef M. Penninger's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jasmin Taubenschmid

Austrian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

Karl Mechtler

Austrian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

Shane J. Cronin

Austrian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

Ulrich Elling

Austrian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

Ali Hafezi-Moghadam

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Cory D. Rillahan

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge